

Goutham Narla

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9143338/publications.pdf>

Version: 2024-02-01

142
papers

5,700
citations

57719

44
h-index

82499

72
g-index

147
all docs

147
docs citations

147
times ranked

6797
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | All roads lead to <sc>PP</sc>2A: exploiting the therapeutic potential of this phosphatase. FEBS Journal, 2016, 283, 1004-1024. | 2.2 | 244 |
| 2 | microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelialâ€mesenchymal transition. Nature Communications, 2014, 5, 2977. | 5.8 | 226 |
| 3 | A Germline DNA Polymorphism Enhances Alternative Splicing of the KLF6 Tumor Suppressor Gene and Is Associated with Increased Prostate Cancer Risk. Cancer Research, 2005, 65, 1213-1222. | 0.4 | 202 |
| 4 | The Kruppel-Like Factor 6 Genotype Is Associated With Fibrosis in Nonalcoholic Fatty Liver Disease. Gastroenterology, 2008, 135, 282-291.e1. | 0.6 | 177 |
| 5 | Mutations in Capillary Morphogenesis Gene-2 Result in the Allelic Disorders Juvenile Hyaline Fibromatosis and Infantile Systemic Hyalinosis. American Journal of Human Genetics, 2003, 73, 957-966. | 2.6 | 174 |
| 6 | Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancerâ†. Gastroenterology, 2004, 126, 1090-1103. | 0.6 | 165 |
| 7 | Kruppel-like Transcription Factor 6 Regulates Inflammatory Macrophage Polarization. Journal of Biological Chemistry, 2014, 289, 10318-10329. | 1.6 | 155 |
| 8 | Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. Journal of Clinical Investigation, 2017, 127, 2081-2090. | 3.9 | 155 |
| 9 | Kruppel-like Factor-6 Promotes Preadipocyte Differentiation through Histone Deacetylase 3-dependent Repression of DLK1. Journal of Biological Chemistry, 2005, 280, 26941-26952. | 1.6 | 153 |
| 10 | Cyclin-Dependent Kinase Inhibition by the KLF6 Tumor Suppressor Protein through Interaction with Cyclin D1. Cancer Research, 2004, 64, 3885-3891. | 0.4 | 152 |
| 11 | Targeted Inhibition of the KLF6 Splice Variant, KLF6 SV1, Suppresses Prostate Cancer Cell Growth and Spread. Cancer Research, 2005, 65, 5761-5768. | 0.4 | 151 |
| 12 | Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology, 2004, 40, 1047-1052. | 3.6 | 142 |
| 13 | Therapeutic targeting of PP2A. International Journal of Biochemistry and Cell Biology, 2018, 96, 182-193. | 1.2 | 138 |
| 14 | The apolipoprotein(a) gene is regulated by sex hormones and acuteâ€phase inducers in YAC transgenic mice. Nature Genetics, 1995, 9, 424-431. | 9.4 | 120 |
| 15 | PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. Science Translational Medicine, 2018, 10, . | 5.8 | 116 |
| 16 | The role of KLF6 and its splice variants in cancer therapy. Drug Resistance Updates, 2009, 12, 1-7. | 6.5 | 112 |
| 17 | Selective PP2A Enhancement through Biased Heterotrimer Stabilization. Cell, 2020, 181, 688-701.e16. | 13.5 | 107 |
| 18 | Roles of KLF6 and KLF6-SV1 in Ovarian Cancer Progression and Intraperitoneal Dissemination. Clinical Cancer Research, 2006, 12, 3730-3739. | 3.2 | 103 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Targeting PP2A in cancer: Combination therapies. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2019, 1866, 51-63. | 1.9 | 99 |
| 20 | KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. <i>Journal of Clinical Investigation</i> , 2008, 118, 2711-2721. | 3.9 | 97 |
| 21 | Ras Promotes Growth by Alternative Splicing-Mediated Inactivation of the KLF6 Tumor Suppressor in Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2008, 134, 1521-1531. | 0.6 | 96 |
| 22 | IKK β negatively regulates ASC-dependent inflammasome activation. <i>Nature Communications</i> , 2014, 5, 4977. | 5.8 | 96 |
| 23 | CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation. <i>Cancer Discovery</i> , 2019, 9, 1538-1555. | 7.7 | 88 |
| 24 | Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells. <i>International Journal of Cancer</i> , 2009, 125, 774-782. | 2.3 | 87 |
| 25 | Kruppel-like Factor 15 (KLF15) Is a Key Regulator of Podocyte Differentiation. <i>Journal of Biological Chemistry</i> , 2012, 287, 19122-19135. | 1.6 | 87 |
| 26 | Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6. <i>Oncogene</i> , 2004, 23, 5077-5083. | 2.6 | 84 |
| 27 | Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. <i>Journal of Clinical Investigation</i> , 2012, 122, 2637-2651. | 3.9 | 79 |
| 28 | Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. <i>Journal of Hepatology</i> , 2007, 46, 645-654. | 1.8 | 75 |
| 29 | Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma. <i>International Journal of Cancer</i> , 2007, 121, 1390-1395. | 2.3 | 73 |
| 30 | Loss of Matrix Metalloproteinase-2 Amplifies Murine Toxin-Induced Liver Fibrosis by Upregulating Collagen I Expression. <i>Digestive Diseases and Sciences</i> , 2011, 56, 406-416. | 1.1 | 70 |
| 31 | KLF6-SV1 Drives Breast Cancer Metastasis and Is Associated with Poor Survival. <i>Science Translational Medicine</i> , 2013, 5, 169ra12. | 5.8 | 70 |
| 32 | Kruppel-like factor 6 regulates mitochondrial function in the kidney. <i>Journal of Clinical Investigation</i> , 2015, 125, 1347-1361. | 3.9 | 65 |
| 33 | A Functional Role for KLF6-SV1 in Lung Adenocarcinoma Prognosis and Chemotherapy Response. <i>Cancer Research</i> , 2008, 68, 965-970. | 0.4 | 61 |
| 34 | Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2018, 78, 2065-2080. | 0.4 | 60 |
| 35 | Ribosomal protein S19 expression during erythroid differentiation. <i>Blood</i> , 2003, 101, 318-324. | 0.6 | 59 |
| 36 | Reengineered tricyclic anti-cancer agents. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 6528-6534. | 1.4 | 58 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Bisphosphonates inactivate human EGFRs to exert antitumor actions. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17989-17994. | 3.3 | 57 |
| 38 | Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF- κ B, and Cell-Cycle Progression in Non-Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2014, 13, 2203-2214. | 1.9 | 57 |
| 39 | Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells. Cancer Cell, 2020, 38, 129-143.e7. | 7.7 | 57 |
| 40 | Transcriptional Activation of the Insulin-Like Growth Factor I Receptor Gene by the Kruppel-Like Factor 6 (KLF6) Tumor Suppressor Protein: Potential Interactions between KLF6 and p53. Endocrinology, 2004, 145, 3769-3777. | 1.4 | 56 |
| 41 | Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma. Cancer Research, 2019, 79, 209-219. | 0.4 | 56 |
| 42 | Regulation of Kruppel-like Factor 6 Tumor Suppressor Activity by Acetylation. Cancer Research, 2005, 65, 9216-9225. | 0.4 | 53 |
| 43 | Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17995-18000. | 3.3 | 52 |
| 44 | Functional role of the KLF6 tumour suppressor gene in gastric cancer. European Journal of Cancer, 2009, 45, 666-676. | 1.3 | 48 |
| 45 | TGF- β 2 regulates the expression of transcription factor KLF6 and its splice variants and promotes co-operative transactivation of common target genes through a Smad3-Sp1-KLF6 interaction. Biochemical Journal, 2009, 419, 485-495. | 1.7 | 45 |
| 46 | Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma. JCI Insight, 2019, 4, . | 2.3 | 43 |
| 47 | Kruppel Cripples Prostate Cancer. American Journal of Pathology, 2003, 162, 1047-1052. | 1.9 | 41 |
| 48 | Increased alternative splicing of the KLF6 tumour suppressor gene correlates with prognosis and tumour grade in patients with pancreatic cancer. European Journal of Cancer, 2008, 44, 1895-1903. | 1.3 | 41 |
| 49 | The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells. Molecular Cancer Research, 2019, 17, 1815-1827. | 1.5 | 40 |
| 50 | Carcinogen-induced hepatic tumors in KLF6+/ β mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. Hepatology, 2011, 54, 522-531. | 3.6 | 39 |
| 51 | KLF6-SV1 Is a Novel Antiapoptotic Protein That Targets the BH3-Only Protein NOXA for Degradation and Whose Inhibition Extends Survival in an Ovarian Cancer Model. Cancer Research, 2009, 69, 4733-4741. | 0.4 | 38 |
| 52 | The Highly Recurrent PP2A C-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis. Cancer Research, 2019, 79, 4242-4257. | 0.4 | 37 |
| 53 | Lung Adenocarcinoma: Lessons in Translation from Bench to Bedside. Mount Sinai Journal of Medicine, 2010, 77, 597-605. | 1.9 | 36 |
| 54 | KLF6 allelic loss is associated with tumor recurrence and markedly decreased survival in head and neck squamous cell carcinoma. International Journal of Cancer, 2007, 121, 1976-1983. | 2.3 | 34 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers. <i>Journal of Biological Chemistry</i> , 2020, 295, 757-770. | 1.6 | 34 |
| 56 | Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing. <i>Hepatology</i> , 2012, 56, 1361-1370. | 3.6 | 31 |
| 57 | The Transcriptional Activator KrÄppel-like Factor-6 Is Required for CNS Myelination. <i>PLoS Biology</i> , 2016, 14, e1002467. | 2.6 | 31 |
| 58 | Deregulating MYC in a model of HER2+ breast cancer mimics human intertumoral heterogeneity. <i>Journal of Clinical Investigation</i> , 2019, 130, 231-246. | 3.9 | 31 |
| 59 | KLF6 degradation after apoptotic DNA damage. <i>FEBS Letters</i> , 2006, 580, 6981-6986. | 1.3 | 30 |
| 60 | Loss of hepatic aldolase B activates Akt and promotes hepatocellular carcinogenesis by destabilizing the Aldob/Akt/PP2A protein complex. <i>PLoS Biology</i> , 2020, 18, e3000803. | 2.6 | 29 |
| 61 | Monotherapy efficacy of blood-brain barrier permeable small molecule reactivators of protein phosphatase 2A in glioblastoma. <i>Brain Communications</i> , 2020, 2, fcaa002. | 1.5 | 28 |
| 62 | The impact of phosphatases on proliferative and survival signaling in cancer. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 2695-2718. | 2.4 | 27 |
| 63 | CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis. <i>Cancer Research</i> , 2021, 81, 4319-4331. | 0.4 | 26 |
| 64 | RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth. <i>Journal of Clinical Investigation</i> , 2019, 129, 1641-1653. | 3.9 | 25 |
| 65 | Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors. <i>Oncogene</i> , 2020, 39, 703-717. | 2.6 | 24 |
| 66 | Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers. <i>Journal of Biological Chemistry</i> , 2020, 295, 757-770. | 1.6 | 24 |
| 67 | Tumor suppressor activity of KLF6 mediated by downregulation of the PTTG1 oncogene. <i>FEBS Letters</i> , 2010, 584, 1006-1010. | 1.3 | 22 |
| 68 | A Genome-Wide Pooled shRNA Screen Identifies PPP2R2A as a Predictive Biomarker for the Response to ATR and CHK1 Inhibitors. <i>Cancer Research</i> , 2020, 80, 3305-3318. | 0.4 | 22 |
| 69 | Phosphoproteomics Profiling of Non-small Cell Lung Cancer Cells Treated with a Novel Phosphatase Activator. <i>Proteomics</i> , 2017, 17, 1700214. | 1.3 | 21 |
| 70 | Mistletoe extract Fraxini inhibits the proliferation of liver cancer by down-regulating c-Myc expression. <i>Scientific Reports</i> , 2019, 9, 6428. | 1.6 | 21 |
| 71 | Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma. <i>Lung Cancer</i> , 2009, 66, 292-297. | 0.9 | 19 |
| 72 | Sex steroids have differential effects on growth and gene expression in primary human prostatic epithelial cell cultures derived from the peripheral versus transition zones. <i>Carcinogenesis</i> , 2006, 27, 216-224. | 1.3 | 18 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Insulin-Like Growth Factor-I Regulates Kruppel-Like Factor-6 Gene Expression in a p53-Dependent Manner. <i>Endocrinology</i> , 2008, 149, 1890-1897. | 1.4 | 18 |
| 74 | Sprague Dawley <i>Rag2</i> -Null Rats Created from Engineered Spermatogonial Stem Cells Are Immunodeficient and Permissive to Human Xenografts. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2481-2489. | 1.9 | 18 |
| 75 | KLF6 is one transcription factor involved in regulating acid ceramidase gene expression. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 2005, 1732, 82-87. | 2.4 | 17 |
| 76 | Challenges and Reinterpretation of Antibody-Based Research on Phosphorylation of Tyr307 on PP2Ac. <i>Cell Reports</i> , 2020, 30, 3164-3170.e3. | 2.9 | 15 |
| 77 | Targeting UHRF1-dependent DNA repair selectively sensitizes KRAS mutant lung cancer to chemotherapy. <i>Cancer Letters</i> , 2020, 493, 80-90. | 3.2 | 14 |
| 78 | Emerging Roles of Kruppel-Like Factor 6 and Kruppel-Like Factor 6 Splice Variant 1 in Ovarian Cancer Progression and Treatment. <i>Mount Sinai Journal of Medicine</i> , 2009, 76, 557-566. | 1.9 | 13 |
| 79 | Targeting protein phosphatase PP2A for cancer therapy: development of allosteric pharmaceutical agents. <i>Clinical Science</i> , 2021, 135, 1545-1556. | 1.8 | 13 |
| 80 | Increased expression of the oncogenic <i>KLF6</i> -SV1 transcript in human glioblastoma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 1167-1170. | 1.4 | 12 |
| 81 | Reply:. <i>Hepatology</i> , 2005, 41, 682-683. | 3.6 | 11 |
| 82 | Protein phosphatase 2A controls ongoing DNA replication by binding to and regulating cell division cycle 45 (CDC45). <i>Journal of Biological Chemistry</i> , 2019, 294, 17043-17059. | 1.6 | 11 |
| 83 | PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3 β -Mediated c-Myc and Pim-1 Proteasomal Degradation. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 676-690. | 1.9 | 10 |
| 84 | The SRG rat, a Sprague-Dawley <i>Rag2/Il2rg</i> double-knockout validated for human tumor oncology studies. <i>PLoS ONE</i> , 2020, 15, e0240169. | 1.1 | 8 |
| 85 | Protein phosphatase 2A Δ 1 regulates Δ 2 protein expression and stability. <i>Journal of Biological Chemistry</i> , 2019, 294, 5923-5934. | 1.6 | 7 |
| 86 | Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia". <i>Science Translational Medicine</i> , 2019, 11, . | 5.8 | 6 |
| 87 | Allosteric activation of PP2A inhibits experimental abdominal aortic aneurysm. <i>Clinical Science</i> , 2021, 135, 2085-2097. | 1.8 | 5 |
| 88 | Specificity of research antibodies: "trust is good, validation is better". <i>Human Pathology</i> , 2018, 72, 199-201. | 1.1 | 4 |
| 89 | Development and comparison of novel bioluminescent mouse models of pancreatic neuroendocrine neoplasm metastasis. <i>Scientific Reports</i> , 2021, 11, 10252. | 1.6 | 4 |
| 90 | Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma. <i>Cancer Research</i> , 2022, 82, 721-733. | 0.4 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | The role of kruppel-like factor 6 (KLF6) in colorectal neoplasia. <i>Gastroenterology</i> , 2003, 124, A13. | 0.6 | 2 |
| 92 | Corrigendum to "Reengineered tricyclic anti-cancer agents" [Bioorg. Med. Chem. 23 (2015) 6528-6534]. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 7487. | 1.4 | 2 |
| 93 | Mistletoe Extract <i>Viscum Fraxini</i> -2 for Treatment of Advanced Hepatocellular Carcinoma: A Case Series. <i>Case Reports in Oncology</i> , 2021, 14, 224-231. | 0.3 | 2 |
| 94 | Kruppel-like Factors and the Liver. , 2009, , 141-150. | | 2 |
| 95 | Abstract 1155: The SRGM rat: A novel SCID rat for humanization studies. , 2018, , . | | 2 |
| 96 | Splice of Life for Cancer: Missplicing of PPP2R5A by Mutant SF3B1 Leads to MYC Stabilization and Tumorigenesis. <i>Cancer Discovery</i> , 2020, 10, 765-767. | 7.7 | 1 |
| 97 | PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation. <i>Blood</i> , 2019, 134, 1276-1276. | 0.6 | 1 |
| 98 | Abstract 1885: Targeting the FOXO1/KLF6 transcriptional network to modulate response to anti-EGFR based therapy. , 2012, , . | | 1 |
| 99 | Abstract 5314: An oncogenic splice variant of the KLF6 tumor suppressor gene is associated with poor survival and is a potent driver of breast cancer metastasis. , 2012, , . | | 1 |
| 100 | Abstract 2698: Phosphoproteomics-guided anticancer drug combination design with a novel small-molecule PP2A activator. , 2018, , . | | 1 |
| 101 | MoBaS on Phosphorylation Data. , 2016, , . | | 0 |
| 102 | Lulling the Cancer Cell into an Eternal Sleep. <i>Cancer Research</i> , 2019, 79, 1756-1757. | 0.4 | 0 |
| 103 | Food and science: Lessons learned from a great chef. <i>American Journal of Hematology</i> , 2021, 96, 1062-1063. | 2.0 | 0 |
| 104 | Kruppel-like Factors KLF6 and KLF6-SV1 in the Diagnosis and Treatment of Cancer. , 2009, , 223-244. | | 0 |
| 105 | Abstract 2899: Restoring sensitivity to anti-EGFR-based therapy in lung adenocarcinoma by downstream modulation of the FOXO1/KLF6 transcriptional network. , 2011, , . | | 0 |
| 106 | Taking the Road Less Traveled: RAS Meets PI3K/PDK1. <i>Science Translational Medicine</i> , 2013, 5, . | 5.8 | 0 |
| 107 | Bringing Down the House by Targeting the Scaffold. <i>Science Translational Medicine</i> , 2013, 5, . | 5.8 | 0 |
| 108 | Of Mice and Men. <i>Science Translational Medicine</i> , 2013, 5, . | 5.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Drugging the Undruggable. Science Translational Medicine, 2013, 5, . | 5.8 | 0 |
| 110 | A New Achilles Heel for Prostate Cancer. Science Translational Medicine, 2013, 5, . | 5.8 | 0 |
| 111 | Out with the New, In with the Old. Science Translational Medicine, 2013, 5, . | 5.8 | 0 |
| 112 | Abstract B47: microRNA-181a plays a critical role in ovarian cancer progression through the regulation of epithelial-mesenchymal transition. , 2013, , . | | 0 |
| 113 | A New Kid on the Block. Science Translational Medicine, 2013, 5, . | 5.8 | 0 |
| 114 | Shiva the Destroyer: Targeting the Destruction of RNA Polymerase for Cancer Treatment. Science Translational Medicine, 2014, 6, . | 5.8 | 0 |
| 115 | Are Two Heads Really Better than One?. Science Translational Medicine, 2014, 6, . | 5.8 | 0 |
| 116 | Enhanced antitumor activity of erlotinib in combination with quinacrine in EGFR WT and L858R/T790M mutant NSCLC.. Journal of Clinical Oncology, 2014, 32, e22153-e22153. | 0.8 | 0 |
| 117 | Abstract 1616: Phosphoprotein enrichment pathway analysis tools for studying cancer signaling. , 2014, , . | | 0 |
| 118 | Abstract A38: Therapeutic targeting of oncogenic KRAS signaling using a novel small molecule agonist of the PP2A tumor suppressor gene. , 2014, , . | | 0 |
| 119 | Abstract 5329: Development of small molecule activators of protein phosphatase 2A for the treatment of lung cancer. , 2015, , . | | 0 |
| 120 | Abstract SY38-03: Targeting post-translational activation of MYC for the treatment of cancer. , 2015, , . | | 0 |
| 121 | Abstract B21: Protein phosphatase 2A (PP2A) activation functions synergistically with kinase inhibition in pancreatic cancer. , 2015, , . | | 0 |
| 122 | Abstract B49: Using small molecule activators of PP2A to negatively regulate c-myc in small cell lung cancer. , 2015, , . | | 0 |
| 123 | Abstract PR04: Cancer drug response networks built for comparative cancer pharmacogenomics identifies combination therapies for repositioning. , 2015, , . | | 0 |
| 124 | Abstract 3865: Therapeutic activation of protein phosphatase 2A for the treatment of lung cancer. , 2016, , . | | 0 |
| 125 | Abstract 3857: Pharmacological reactivation of the tumor suppressor protein phosphatase 2A as a novel approach for the treatment of breast cancer. , 2016, , . | | 0 |
| 126 | Abstract 4173: Drug target mutations as a mechanism of acquired resistance to small molecules activators of protein phosphatase 2a. , 2017, , . | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Abstract 1827: Direct activation of the tumor suppressor protein phosphatase 2A as a therapeutic strategy for TKI-resistant lung adenocarcinoma. , 2018, , . | | 0 |
| 128 | Drug Combinations Co-Targeting Myeloid Cell Leukemia-1 (Mcl-1) Protein Can Overcome Microenvironmentally-Induced Multi-Drug Tolerance in Non-Hodgkin Lymphomas. Blood, 2018, 132, 2649-2649. | 0.6 | 0 |
| 129 | Abstract 1059: A case study: OncoRat is a viable patient avatar for a NSCLC patient with a Y1248H Met activating mutation. , 2019, , . | | 0 |
| 130 | Abstract B016: CDK7 inhibition suppresses AR addicted Castration-Resistant Prostate Cancer through MED1 inactivation. , 2019, , . | | 0 |
| 131 | Modulation of the Tumor Suppressor Protein PP2A Using a Small Molecule Agonist Overcomes Multi-Drug Resistance through Mitochondrial Permeability Transition Pore (MPTP) Dependent Induction of Apoptosis in Chronic Lymphocytic Leukemia. Blood, 2020, 136, 15-17. | 0.6 | 0 |
| 132 | Integrating Medical Genetics Into Precision Oncology Practice in the Veterans Health Administration: The Time Is Now. JCO Oncology Practice, 2022, , OP2100693. | 1.4 | 0 |
| 133 | Title is missing!. , 2020, 18, e3000803. | | 0 |
| 134 | Title is missing!. , 2020, 18, e3000803. | | 0 |
| 135 | Title is missing!. , 2020, 18, e3000803. | | 0 |
| 136 | Title is missing!. , 2020, 18, e3000803. | | 0 |
| 137 | Title is missing!. , 2020, 18, e3000803. | | 0 |
| 138 | Title is missing!. , 2020, 18, e3000803. | | 0 |
| 139 | The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies. , 2020, 15, e0240169. | | 0 |
| 140 | The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies. , 2020, 15, e0240169. | | 0 |
| 141 | The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies. , 2020, 15, e0240169. | | 0 |
| 142 | The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies. , 2020, 15, e0240169. | | 0 |